Physician profile
Philip Micale
NPI 1750354346
$3,785.42
in general payments reported to CMS, 2019-2025
22 companies · $806 in 2025
The $806 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $347 · 2021: $690 · 2022: $391 · 2023: $290 · 2024: $347 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.99 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $627.14 | 2019-2025 | Relistor, Trulance, Plenvu |
| Janssen Biotech, INC. | $309.19 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $269.35 | 2019-2025 | Entyvio, Eohilia |
| Allergan, INC. | $171.18 | 2019-2020 | |
| Gilead Sciences, INC. | $167.26 | 2019-2021 | |
| Pfizer INC. | $163.32 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $154.84 | 2021-2024 | |
| Intuitive Surgical, INC. | $131.52 | 2025 | |
| Intercept Pharmaceuticals, INC. | $73.67 | 2019-2025 | |
| Redhill Biopharma INC. | $56.87 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Aimmune Therapeutics, INC. | $56.11 | 2025 | Zenpep |
| Vivus LLC | $45.81 | 2022-2025 | Pancreaze, Qsymia |
| Madrigal Pharmaceuticals | $37.46 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $36.80 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $36.09 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $31.03 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $30.65 | 2021-2022 | |
| Celgene Corporation | $28.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.18 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $19.01 | 2025 | Wegovy |
| Celltrion USA INC. | $17.11 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Micale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.